Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Wang

Internal Medicine Fairhope, AL Medical Doctor

NPI 1821286451 CMS profile 219200

150 S Ingleside St Ste 6, Fairhope, AL 36532

Open in the dashboard

General payments

$10,916

728 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Wang of Fairhope, AL is reported in the CMS Open Payments database as having received $10,916 across 728 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,188 72
2024 General $1,219 74
2023 General $1,379 82
2022 General $1,438 98
2021 General $2,051 144
2020 General $1,810 122
2019 General $1,831 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Wang
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Frank Wang were reported at $1,188. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Frank Wang Internal Medicine median Middle half National median
2019 $1,831 $159 $48–$570 $163
2020 $1,810 $119 $33–$402 $114
2021 $2,051 $135 $37–$521 $132
2022 $1,438 $141 $42–$496 $149
2023 $1,379 $149 $45–$519 $160
2024 $1,219 $154 $47–$537 $164
2025 $1,188 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,661 136 payments
  2. AbbVie, Inc. $894 72 payments
  3. Lilly USA, LLC $880 60 payments
  4. Pfizer Inc. $825 65 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $646 34 payments
  6. AstraZeneca Pharmaceuticals LP $526 30 payments
  7. Janssen Pharmaceuticals, Inc $430 32 payments
  8. Amarin Pharma Inc. $429 21 payments
  9. Allergan Inc. $419 37 payments
  10. GlaxoSmithKline, LLC. $410 28 payments
  11. Other $3,796 213 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,776 724 payments
  2. Education $140 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,208 111 payments
  2. RYBELSUS $1,036 87 payments
  3. XIFAXAN $703 37 payments
  4. ELIQUIS $446 27 payments
  5. XARELTO $412 30 payments
  6. TRELEGY ELLIPTA $386 26 payments
  7. MOUNJARO $383 22 payments
  8. Vascepa $371 18 payments
  9. UBRELVY $342 21 payments
  10. Kerendia $330 19 payments
  11. Other $8,962 651 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

4,916

Median for Internal Medicine: 777

Drug cost

$339,063

Median for Internal Medicine: $73,373

Branded share of claims

18.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 63 $70,154
Eliquis Apixaban Brand 41 $46,629
Xarelto Rivaroxaban Brand 24 $34,083
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $24,287
Mounjaro Tirzepatide Brand 23 $23,686
Myrbetriq Mirabegron Brand 16 $15,531
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $13,506
Linzess Linaclotide Brand 17 $12,790
Rybelsus Semaglutide Brand 11 $10,018
Breo Ellipta Fluticasone/Vilanterol Brand 17 $9,693

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$62,390

Of which drugs: $9,318

Medicare patients

181

Average age 78

Services billed

1,554

105 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 54%
Ischemic heart disease 28%
Depression 24%
Cancer 22%
Osteoporosis 19%
Diabetes 18%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 35 35 $2,752
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 22 56 $290

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$186 23 —
YUPELRI
$75 — —
RYBELSUS
$73 11 —
Ozempic
$73 63 —
AIRSUPRA
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

728 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record